01
Cash & equivalents decreased 11.8%
Cash & equivalents changed -11.8% from the comparable as-filed period.
$53.8M→$47.5MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTPrime Medicine, Inc.'s latest supported as-filed period reports revenue of $4.6M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -11.8% from the comparable as-filed period.
Net income changed +19.9% from the comparable as-filed period.
Operating income changed +18.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
PRME · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-053883SEC ↗8-KAug 6, 2026Period Aug 6, 20260001628280-26-053878SEC ↗8-KJul 8, 2026Period Jul 6, 20260001628280-26-047590SEC ↗4Jun 8, 2026Period Jun 5, 20260001628280-26-041579SEC ↗4Jun 8, 2026Period Jun 5, 20260001628280-26-041575SEC ↗4Jun 8, 2026Period Jun 5, 20260001628280-26-041572SEC ↗4Jun 8, 2026Period Jun 5, 20260001628280-26-041569SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 5, 2026Filed Jun 8, 2026 | Schenkein David PDirector | Grant Or AwardDirect | 75,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -19.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed -23.1% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001628280-26-041566